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Abstract
TNF-related apoptosis- inducing ligand (TRAIL/APO-
2L) is a member of the TNF family that promotes
apoptosis by binding to the transmembrane receptors
TRAIL-R1/DR4 and TRAIL-R2/DR5. Its cytotoxic activ-
ity is relatively selective to the human tumor cell lines
without much effect on the normal cells. Hence, it exerts
an antitumor activity without causing toxicity, as
apparent by studies with several xenograft models. This
review discusses the intracellular mechanisms by which
TRAIL induces apoptosis. The major pathway of its
action proceeds through the formation of DISC and
activation of caspase-8. The apoptotic processes,
therefore, follow two signaling pathways, namely the
mitochondrial - independent activation of caspase-3,
and mitochondrial -dependent apoptosis due to cleav-
age of BID by caspase-8, the formation of apoptosomes,
and activation of caspase-9 and the downstream
caspases. Bcl-2 and Bcl-XL have no effect on TRAIL-
induced apoptosis in lymphoid cells, whereas these
genes block or delay apoptosis in nonlymphoid cancer
cells. TRAIL participates in cytotoxicity mediated by
activated NK cells, monocytes, and some cytotoxic T
cells. Hence, TRAIL may prove to be an effective
antitumor agent. In addition, it may enhance the
effectiveness of treatment with chemotherapeutic drugs
and irradiation. Nontagged Apo-2L/TRAIL does not
cause hepatotoxicity in monkeys and chimpanzees
and in normal human hepatocytes. Thus, nontagged
Apo-2L/TRAIL appears to be a promising new candi-
date for use in the treatment of cancer. Neoplasia (2001)
3, 535–546.
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Introduction
Programmed cell death or apoptosis is a genetically
controlled mechanism that is essential for the maintenance
of tissue homeostasis involving development and the
elimination of unwanted cells. There are a number of
ligand-receptor families that are involved in this phenom-
enon. Some of the members of this family are TNF-,
CD95L/FasL/Apo-1L, and TRAIL/APO-2L. They regulate
many biologic functions including cell metabolism, prolifer-
ation, cytokine production, and apoptosis [68,96,138] .
TRAIL/APO-2L specifically kills transformed and cancer
cells through binding with death receptors (DR4 and DR5).
Most normal cells appear to be resistant to TRAIL activation,
suggesting a higher activity of TRAIL with its receptors on
tumor cells. Binding of DR4 or DR5 with TRAIL results in a
caspase-activating signal leading to apoptosis [68,94] ) .
Recent studies have shown that systemic administration of
TRAIL is physiologically safe in mice and is effective in killing
human breast or colon xenografted tumors [31] . It also
prolongs survival of tumor-bearing mice [31] . TRAIL
participates in cytotoxicity mediated by activated NK cells
[60] , monocytes [41] , and some cytotoxic T cells [59,124] .
The objective of this paper is to review the intracellular
mechanisms by which TRAIL induces apoptosis and to
assess its clinical use in cancer therapy.
TRAIL Receptors
Recent studies have identified four distinct cell surface
TRAIL receptors: (a) TRAIL-R1 (DR4) [91,93] ; (b) TRAIL-
R2 (DR5/TRICK2/KILLER) [93,102,104,107,133,140] ; (c )
TRAIL-R3 (DcR1/TRID/LIT) [18,102] ; and (d) TRAIL-R4
(DcR2/TRUNDD)17,80,92] (Figure 1 ) . All these receptors
have high sequence homology in their extracellular domains.
The fifth receptor is the soluble osteoprotegerin, which may
act as a decoy receptor and does not induce apoptosis [29] .
Although TRAIL binds with all the receptors, the function of
their intracellular domains is not uniform. The intracellular
domains of DR4 and DR5 have been found to be essential
for induction of apoptosis following receptor ligation
[34,93,102,133,140] . TRAIL-R3/DcR1 and TRAIL-R4/
DcR2/TRUNDD lack a functional cytoplasmic domain
[16–18,29,80,91,107] . TRAIL-R3 and TRAIL-R4 may
serve as ‘‘decoys’’ that compete with TRAIL-R1/TRAIL-
R2 for binding to the TRAIL. Overexpression of either DcR1
or DcR2 protein confers protection against TRAIL- induced
apoptosis [91,107] .
The signal transduction machinery that couples these
receptors to the initiation of the cell death cascade is not well
understood. Overexpression of DR4 or DR5 can induce
apoptosis independent of ligand binding in vitro, suggesting
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that the initiation of apoptosis could bypass ligand binding.
The signal can be directly transduced to downstream sites
that activate caspases. The cytoplasmic sequence of death
receptors contains a shared 80-amino-acid death domain
that, upon ligand binding, associates with a similar domain
found in adaptor proteins such as FAS-associated with
death domain (FADD) [34,39,103] . In Fas/FasL signaling,
it has been shown that receptor preassociation is required
for ligand attachment [10,109] . Association of death
receptors with their cognate ligands results in receptor
trimerization, and recruitment of adaptor protein [2 ] . The
adaptor proteins also contain an effector domain that
constitutively binds to cysteine proteases (caspases) that
cleave specific proteins. The two caspases predominantly
bound to these adaptor molecules are caspase-8 and
caspase-10 [2,103] . Once recruited by association of
adaptor proteins with death receptors, these caspases are
trans-proteolyzed resulting in their activation. Caspase-8
activation initiates two pathways (mitochondrial -dependent
and - independent pathways) , which result in activation of
caspase-3 [6,117] . This ultimately results in an irreversible
commitment of cells to undergo apoptosis [2,103] .
Recently, it has been reported that a GTP binding protein
DAP3 binds directly to the death domain of DR4 and DR5
and causes TRAIL- induced apoptosis by associating with
FADD [81] . In addition, recruitment of receptor - interacting
protein (RIP) to the receptor complex has been shown to
cause a caspase-8–independent form of cell death with
necrotic morphology [46] . It is therefore, important to
assess TRAIL- induced cell death employing assays for
both apoptosis and necrosis.
The extracellular domains of TNF receptor family mem-
bers contain multiple disulfide bridges, which stabilize their
configuration [5] . However, antiparallel  -sheets configu-
ration of the receptor facilitates binding of the ligand [26,56] .
TRAIL possesses a free Cys residue (Cys230) . It has been
shown that the Cys230 residue of TRAIL is an essential
moiety of its proapoptotic activity. This is apparent from the
loss of such activity if trimers of TRAIL formed by disulfide
cross- linking are used. Data also suggest that the unoxi-
dized (nondisulfide) TRAIL fits better into the receptor than
the TRAIL modified by establishment of disulfide bridges.
The higher activity of the TRAIL containing free Cys-SH is
also apparent from the enhancement of its effect in the
presence of certain trace metals such as Zn2+ . Such ions are
well known to stabilize the sulfhydryl group by coordination.
Experiments involving the use of TRAIL in combination with
these reagents in promoting its biologic effectiveness have
not been apparently done.
FADD Is Involved in DR4- and DR5-Mediated Apoptosis
The onward cascade of apoptosis triggered by the binding of
TRAIL to DRs was initially thought to be propagated further
by the binding of FADD to the cytoplasmically located death
domain of DRs [11,47,102,131] . However, some studies
have shown that propagation of the process takes place also
in the FADD /  mice, suggesting the possibility of the
involvement of other adaptor molecules capable of binding to
DRs, in addition to FADD [136,141] . However, more recent
studies have demonstrated that FADD /  mouse embry-
onic fibroblast cells stably transfected with TRAIL receptors
Caspase- 8
DR4/DR5
TRAIL
DcR1 DcR2
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RIP
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DAP3
Apoptosis Necrosis
No Cell Death
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Figure 1. Schematic representation of TRAIL receptors and the components of TRAIL -DISC (death - inducing signaling complex ). Trimerization of TRAIL receptors
(TRAIL -R1 /DR4 and TRAIL -R2 /DR5 ) initiates recruitment of adaptor protein FADD. It appears that a GTP -binding adaptor protein DAP3 couples TRAIL
receptors to FADD. FADD contains a death effector domain (DD ) that promotes recruitment of procaspase -8 to the DISC, by homotypic interactions between the
DD present on FADD and procaspase -8. The induced proximity of procaspase -8 molecules is postulated to cause their activation by autocatalytic processes. RIP
may also bind to these DR4 and DR5, initiating a cascade causing cell necrosis. Decoy receptors DcR1 and DcR2 lack death domains and do not induce apoptosis.
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are resistant to TRAIL-mediated cell death [70] . TRAIL
receptors stably transfected into heterozygous FADD+/
cells or FADD /  cells reconstituted with a FADD retroviral
construct are sensitive to the cytotoxic effects of TRAIL [70] .
Therefore, it is highly likely that FADD is required for DR4-
and DR5-mediated apoptosis.
We, and others, have shown that the cell lines deficient in
FADD or caspase-8 are resistant to Fas- induced cell signals
[52,53,117] . Incorporation of caspase-8 into TRAIL-recep-
tor DISC is defective in cells lacking caspase-8 and FADD
[6,66,110,117] ) . In addition, FADD cannot be substituted by
other FADD- like proteins, and caspase-10 cannot replace
caspase-8 for DISC formation [6,117] . TRAIL also fails to
activate caspase-3 in FADD-deficient Jurkat cells [6,117] .
Wild- type Jurkat cells are sensitive to TRAIL- induced
apoptosis, whereas FADD-deficient and caspase-8–defi-
cient Jurkat cells are resistant to TRAIL- induced apoptosis
[6,117] . This resistance is attributable to a deficiency in
caspase-8 or in FADD expression, rather than a reduced
expression of caspase-3 or DR5. Therefore, FADD recruit-
ment to DISC and caspase-8 activation are considered
necessary events during TRAIL-DR5 mediated apoptosis.
Caspase Cascade in TRAIL- Induced Apoptosis
Caspases are a group of cysteine proteases requiring
specifically the presence of aspartate at the cleavage site.
The caspase gene family has at least 14 mammalian
members [1] . These are initially expressed as single-chain
zymogens, which upon apoptotic signaling are activated by
proteolytic processing, either by autoactivation, transactiva-
tion, or by cleavage by other caspases [36,139] . Once
activated, they proteolytically cleave a multitude of cellular
proteins, leading to apoptosis. Therefore, the caspase
activation is a key regulatory point in the commitment of
the cell to apoptosis.
TRAIL signaling pathways involve two caspase cascades
[67,68,90,117] . After initial activation of caspase-8 by
TRAIL-DISC, divergence of signal occurs in two directions:
(1) direct activation of caspase-3 without the involvement of
mitochondria, and (2) formation of apoptosomes (mito-
chondrial proteins, dATP and Apaf-1) , which lead to
activation of caspase-9 (describe below) [42,43,74,79] .
These two pathways appear to converge on caspase-3. In a
mechanism not entirely understood, cytochrome c and
dATP/ATP act as cofactors and stimulate Apaf-1 self -
oligomerization. Once activated, caspase-9 can activate
effector caspase-3 and -7 that finally dismantle the cell
[76,111,145, ] (Figure 2 ) . The decline in mitochondrial
membrane potential ( m) can be blocked by caspase-8
inhibitor, but not by caspase-9 inhibitor [62,64,117] . Thus,
caspase-8 links the apoptotic signal from the activated
TRAIL-DR to mitochondria leading to dissipation of m and
directly to the downstream apoptosis -executing caspases.
APOPTOSIS
Caspase-8
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Caspase-3, -7
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Figure 2. Intracellular mechanism of TRAIL - induced apoptosis. Apoptosis pathways activated by TRAIL and mitochondria are depicted. Ligation of death receptors
by TRAIL leads to formation of DISC which in turn initiates two pathways: ( a ) activation of caspase -8 leading to apoptosis, and (b ) activation of Bid to truncated Bid
which in turn regulates mitochondrial functions. Cytochrome c along with Apaf - 1 and dATP forms apoptosomes which activate caspase -9. Active forms of caspase -
8 and -9 initiate a cascade of effector caspases such as caspase -3 and -7. Activated caspases cleaved several substrates leading to apoptosis. Bcl - 2 and Bcl -XL
seem to delay or have no affect on apoptosis - related mitochondrial events. IAPs inhibit caspase -3, - 7, and -9. Smac /DIABLO inhibits XIAP / cIAP.
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Cleavage of the downstream protease, caspase-3, seems to
occur due to activation of either pathway (Figure 2 ) .
Knowledge on the relative contributions of these two
alternative pathways in TRAIL- induced apoptosis is yet
incomplete.
The mechanisms controlling the release of mitochondrial
proteins are currently under intensive investigation. They
may include opening of a mitochondrial permeability tran-
sition pore (PTP) , the presence of a specific channel for
cytochrome c in the outer mitochondrial membrane or
mitochondrial swelling and rupture of the outer membrane
without a loss in membrane potential [37 ] . Involvement of
the PTP is supported by many reports that the  m
collapses before activation of caspases and apoptosis
[69] . The outer mitochondrial membrane becomes perme-
able to apoptogenic factors such as cytochrome c, Smac/
DIABLO (direct inhibitor of apoptosis binding protein [ IAP]
with low pI) [23,127] and apoptosis - inducing factor (AIF)
[120] . Furthermore, the proapoptotic activity of Smac/
DIABLO is probably independent of the binding to IAPs.
This can mediate the cleavage of DNA during caspase-
independent cell death. TRAIL cleaves several substrates
including DNA repair enzyme poly(ADP-ribose) polymer-
ase (PARP) [117] .
Treatment of cells with TRAIL results in caspase-8
activation, followed by BID (Bcl -2 inhibitory BH3-domain–
containing protein) cleavage at its amino terminus
[42,43,74,79,117] . The truncated BID (tBID) translocates
and gets inserted into the mitochondrial membrane [74] .
The presence of tBID into the mitochondria appears to be a
stress signal and triggers Bax oligomerization and cyto-
chrome c release [37] . Furthermore, BID-deficient mice are
resistant to Fas- induced hepatocellular apoptosis [142] .
Immunodepletion of tBID from subcellular fractions argues
that tBID is required for cytochrome c release from the
mitochondria. Treatment of cells with TRAIL resulted in BID
cleavage, suggesting that BID is a substrate for caspase-8
[62,117] .
Another form of regulation of caspase activation has
recently come to light by the finding that Akt, a serine/
threonine kinase involved in some cell survival pathways,
and p21-Ras, an activator of Akt, induce phosphorylation of
procaspase-9 [9] . In cytosolic extracts prepared from cells
expressing either active Ras or Akt, the cytochrome c–
dependent activation of caspase-9 is abrogated, suggesting
that phosphorylation of procaspase-9 inhibits its processing
and activation. Although it is unclear how phosphorylation
inhibits its processing, it is suggested that it may facilitate
enzyme dimerization through an allosteric mechanism.
Effects of IAPs on TRAIL- Induced Apoptosis
IAPs were discovered by Crook et al. as baculoviral products
[15] . They could suppress apoptosis of cells infected with a
p35-deleted baculoviral strain [15] . Subsequent genetic
and sequence-based experiments identified a group of
cellular IAP homologs in yeasts, C. elegans, Drosophila, and
vertebrates [14,25,45,71,78,100,101,126] . The precise
mechanism of how IAPs inhibit apoptosis is unclear. The
mammalian IAPs, XIAP (MIHA, hILP) , c- IAP1 (MIHB,
HIAP2) , c- IAP2 (MIHC, HIAP1), NAIP, and survivin can
bind to and inhibit caspases. Early genetic evidence
indicated that baculoviral inhibitor of apoptosis repeat
(BIR) domains might be essential for the caspase- inhibitory
function of XIAP, as they bind directly to distinct caspases
(Figure 3 ) . Human IAPs, such as XIAP, c- IAP1, and c- IAP2
inhibit both the initiator caspase-9 and the effector caspase-
3 and -7 [21,27,101,108] . In vitro kinetic studies revealed
BIR1 BIR2 BIR3 RING
Binds and 
inhibits caspase 9Inhibits
caspase 3 and -7
Stabilizes binding
to caspase -3 and -7
Binds to XAF1
Binds to Smac/DIABLO
E3 ubiquitin ligase
Figure 3. Structure and function of XIAP. Functional domains of the XIAP protein. Baculoviral inhibitor of apoptosis repeat (BIR ) domains is essential for the
caspase - inhibitory function of XIAP. XIAP inhibits both the initiator caspase -9 and the effector caspase -3 and -7. XAF1, XIAP -associated factor 1. The function of
the BIR1 domain of XIAP is still unclear.
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that XIAP is the most potent caspase inhibitor in the IAP
family [21,27,101,108] . New structural data also support the
concept that XIAP might inhibit initiator and effector
caspases by different means (Table 1) . Thus, a limited
number of IAPs can inhibit caspases bound to the
apoptosome and, consequently, might prevent the possibility
of an amplification loop outside the complex. Because TRAIL
activates primarily caspase-8, -9, and -3 (and possibly
caspase-7) , it appears that XIAP can inhibit TRAIL- induced
apoptosis [117] .
Overexpression of XIAP protects cells from divergent
apoptotic signals, including ultraviolet irradiation,  - irradi-
ation, and chemotherapeutic drugs. But mice with a targeted
deletion of XIAP are normal and show no signs of
misregulated apoptosis [44] . The loss of XIAP, however,
is accompanied by an increase in the levels of c- IAP1 and c-
IAP2, suggesting that IAP activity is critical for cell survival
and that the loss of XIAP needs to be compensated for.
The Bcl -2 proteins can block only the mitochondrial
branch of apoptosis by preventing the release of cytochrome
c, whereas IAPs block both the mitochondrial - and death-
receptor–mediated pathways of apoptosis by directly bind-
ing to and inhibiting both the initiator and effector caspases.
The discovery of cellular proteins that interact with XIAP and
modulate its antiapoptotic activity points to the critical role of
XIAP in cellular homeostasis. Overexpression of IAP family
proteins inhibits apoptosis induced by Bax and other
proapoptotic Bcl -2 family proteins, which are known for their
ability to target mitochondria and induce cytochrome c
release [8,21,54] . The IAPs, however, do not interfere with
Bax-mediated release of cytochrome c from mitochondria in
vitro, as well as in intact cells [54] , an observation that is
consistent with other data indicating that the human IAPs
block caspase activation and apoptosis downstream of Bax,
Bik, Bak, and cytochrome c [20,21,24,101,121] . The failure
of IAPs to prevent cell death stimuli from triggering
cytochrome c release has important implications for deter-
mining whether cell death will be prevented in the long term
or is merely delayed. These diverse apoptotic inhibitors from
mammals, insects, and their associated viral pathogens are
providing important insight into the regulatory mechanisms of
TRAIL- induced caspase activation and apoptosis.
Recently, a XIAP- interacting protein named XIAP-asso-
ciated factor1 (XAF1) has been identified [77] . XAF1
antagonizes the ability of XIAP to suppress caspase activity
and cell death in vitro. It is not known how XAF1 interacts
with XIAP to inhibit its activity. In contrast to Smac/DIABLO,
XAF1 does not need to be processed, and it seems to be
constitutively able to interact with and inhibit XIAP. Unlike
XIAP, however, which is found primarily in the cytoplasm,
endogenous XAF1 is localized to the nucleus. The different
compartmentalization of XIAP and XAF1 raises the question
of how these two proteins can interact — does XAF1
translocate into the cytoplasm where it inhibits XIAP, or does
XIAP enter the nucleus where it is sequestered by XAF1? It
is conceivable that XIAP could be transported into the
nucleus within the caspase-3 protein complex, where it
would continue to inhibit caspase-3 activity. This caspase-
inhibiting activity could then be relieved by nuclear XAF1, in a
fashion similar to the cytoplasmic inhibition of XIAP by
Smac/DIABLO.
There are several outstanding issues that need to be
addressed experimentally and will probably provide vital
clues about the regulation of XIAP. Understanding the
biology of XIAP not only provides the intellectual satisfaction
of untangling the complex regulatory networks that control
life and death, but it might also supply us with powerful
therapeutic approaches for the treatment of several human
diseases.
Effects of Bcl-2 or Bcl-XL on TRAIL- Induced Apoptosis
and Mitochondrial Dysfunctions
Apoptosis can be induced by both mitochondrial -dependent
and - independent pathways [64,68,69,95,117,134] . Mem-
brane depolarization and subsequent loss of cytochrome c
and other cofactors from the mitochondrial intermembrane
space appear to be the early event in the mitochondrial
dependent pathway [37,69] . Permeabilization of the outer
mitochondrial membrane is controlled by members of the
Bcl -2 family [19] . The antiapoptotic members such as Bcl -2
or Bcl -XL inhibit the release of mitochondrial apoptogenic
factors, whereas the proapoptotic members (e.g., Bax, and
Bak) trigger the release. It is not clear how Bcl -2 family
members modulate permeabilization of the outer mitochon-
drial membrane and also preserve mitochondrial function.
Overexpression of Bcl -2 or Bcl -XL does not block
[62,64,117] TRAIL- induced apoptosis in lymphoid cells,
suggesting tumor cells that have already acquired resistance
to chemotherapeutic drugs by Bcl -2 or Bcl -XL can be killed
by TRAIL. Thus, TRAIL may be a promising candidate for the
treatment of patients carrying drug- resistant tumors. Treat-
ment of CEM, Jurkat, U937, MDA-MD231, and MCF-7 cells
Table 1. Caspase Inhibition by IAP.
IAP gene BIR RING CARD Caspase Inhibition K i ( nm ) References
XIAP 3 1 0 Caspase -3 0.7 [ 73 ]
Caspase -7 0.2 [ 73 ]
Caspase -9 ND
cIAP1 3 1 1 Caspase -3 108 [73 ]
Caspase -7 42 [73 ]
cIAP2 3 1 1 Caspase -3 35 [73 ]
Caspase -7 29 [73 ]
NAIP 3 0 0 Caspase -3 ND
Caspase -7 ND
Livin 1 1 0 Caspase -3 ND
Caspase -7 ND
Caspase -9 ND
Survivin 1 0 0 Caspase -3 20.9 [ 74 ]
Caspase -7 11.5 [ 74 ]
The type and number of functional domains are indicated for each IAP gene.
The inhibitory constants (K i ) for caspase inhibition are shown next to the
target caspase.
ND, not determined; BIR, baculoviral inhibitor of apoptosis repeat; CARD,
caspase recruitment domain; IAP, inhibitor of apoptosis; RING, really
interesting new gene.
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with TRAIL causes a steady decline in  m [62,64,117] .
The time-dependent loss of  m in cells due to TRAIL
treatment is delayed, but not prevented, by the over-
expression of Bcl -2 or Bcl -XL [64,117] . In contrast, over-
expression of Bcl -2 blocks TRAIL- induced apoptosis in
human lung [119] and prostate cancer cells [83,86,99] .
Thus, TRAIL can induce apoptosis through both mitochon-
drial -dependent and - independent pathways, whereas most
anticancer drug- induced apoptosis requires mitochondrial
events and is inhibited by overexpression of Bcl -2 or Bcl -XL
[62,64,113,115,132] .
Role of NFB in TRAIL- Induced Apoptosis
NFB is widely known for its ubiquitous roles in
inflammation, immune responses, cell division, and apop-
tosis [4,128] . NFB is composed of members of the Rel
family that share a 300-amino-acid region, known as the
Rel homology domain, which mediates dimerization,
nuclear translocation, DNA binding, and interaction with
NFB inhibitors [55,128] . Activation of NFB is controlled
by a family of inhibitors, or IBs, that bind to NFB
dimmers and mask the nuclear localization sequence of
NFB, thus retaining the entire complex in the cytoplasm
(Figure 4 ) . Activation of NFB is achieved by the
phosphorylation and activation of the IB kinase ( IKK)
complex. The activated IKK complex specifically phos-
phorylates the IBs, which are then rapidly polyubiquiti-
nated, targeting them for degradation by the proteosome.
This results in release and translocation of NFB dimmers
from the cytoplasm to the nucleus where they bind target
genes and stimulate transcription (Figure 4 ) . NFB
activates a variety of target genes relevant to the human
diseases such as ischemic stroke, Alzheimer’s disease
and Parkinson’s disease, as well as genes that regulate
cell proliferation and mediate cell survival. NFB also
activates the IB gene, thus replenishing the cytoplasmic
pool of its own inhibitor.
     TRAIL
DR4/DR5
FADD
Caspase- 8
I B 
I B 
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IKK
p50p65
p65
p50
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Nucleus
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Figure 4. Involvement of NFB in TRAIL - induced apoptosis. Binding of death receptors DR4 and DR5 with ligand TRAIL results in the activation of NFB. p50 and
p65 subunits of NFB are maintained in the cytoplasm by binding to IB inhibitory proteins. In response to cellular stimulation, IB proteins are phosphorylated (by
IKK ) , ubiquitinated, and degraded. Removal of IB from NFB allows NFB to translocate into the nucleus where it transactivates numerous apoptosis related
genes such as c - IAPs, DR4, DR5, and Bcl -XL.
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The involvement of NFB in TRAIL- induced apoptosis is
not well understood [2] . It seems that TRAIL does not
activate the immune system in vivo, at least in mouse and
monkey. No knockout mice lacking TRAIL or its receptors
have been reported, and so the physiological function of this
death factor system remains elusive. TRAIL activates NFB
in vitro [32,47] . Constitutively active NFB prevents TRAIL-
induced apoptosis in renal cancer cells [89] . However,
NFB activation is not sufficient for protecting cells from
TRAIL- induced apoptosis [47] . It is possible that various
subunits of NFB play different roles in regulating cellular
response of TRAIL. In a recent report, NFB-c-Rel subunit
enhances TRAIL- induced apoptosis by enhancing the
expression of death receptors DR4 and DR5, whereas
NFB-Rel -A inhibits TRAIL- induced apoptosis by increas-
ing the expression of Bcl -XL [98] . Further studies are
needed to confirm the role of specific subunits of NFB in
TRAIL signaling.
Factors Influencing TRAIL Sensitivity in Normal and
Cancer Cells
A critical feature of any approach to cancer treatment is the
ability of selectively interfering with growth or viability of
cancer cells while avoiding or minimizing toxicity to normal
noncancer cells. Several factors have been proposed to be
involved in imposing TRAIL sensitivity, such as the relative
numbers of death and decoy receptors, temperature, and the
relative activities of FLICE- inhibitory protein (FLIP) , cas-
pase-8 and -10, and the constitutively active AKT/PKB.
Delineation of the factors involved in the apoptotic response
of TRAIL is complex. The response also varies with the
species.
The different sensitivities of TRAIL in regulating apoptosis
was proposed due to the higher expression of decoy
receptors in normal cells, but the absence of or lower
expression of these receptors in transformed cells [2,13,73] .
As more cell lines were examined, the expression level of
DR5, DcR1, and DcR2 did not correlate with TRAIL
sensitivity [39,40,65] . It may be possible that TRAIL
sensitivity is primarily regulated at the intracellular level
rather than at the receptor level [40,112] . Further studies
are needed to confirm the involvement of decoy receptors in
TRAIL sensitivity.
Various versions of TRAIL have been found to exert
differential effects on normal human hepatocytes [35] .
Several soluble TRAIL receptor agonists have been used
to test toxicity on normal human hepatocytes in vitro. They
are ( i ) nontagged, soluble and native-sequence TRAIL
(amino acids 114–281) [3 ] , ( ii ) polyhistidine- tagged
recombinant soluble TRAIL (amino acids 114–281) [51] ,
( iii ) recombinant soluble TRAIL fused to a trimerizing leucine
zipper (amino acids 95–281) [135] , and ( iv) agonist
antibody [40,48] . Nontagged, soluble, and native-sequence
TRAIL, and leucine zipper TRAIL did not cause hepatotox-
icity in rat, mouse, cynomolgus monkeys, and chimpanzees
[3,72,135] . In contrast, polyhistidine- tagged TRAIL induced
some apoptosis in cultured human hepatocytes [51] . Non-
tagged soluble TRAIL was nontoxic to normal keratinocytes,
whereas histidine- tagged and leucine zipper- fused TRAIL
were cytotoxic [97] . In addition, histidine- tagged TRAIL
acted as a negative regulator of normal erythropoiesis [144]
and induced apoptosis in lymphocytes [88] . In another study
FLAG-tagged TRAIL induced apoptosis in human brain
[87] . The differences in cytotoxicity are due to the aberrant
biochemical and structural properties of tagged TRAIL. In
particular, native TRAIL contains an internal zinc atom bound
by cysteine residues at position 230 of each subunit, which is
crucial for trimer stability and biologic activity [7 ] . By
comparison, the polyhistidine- tagged recombinant soluble
form of TRAIL does not contain as much zinc as native
TRAIL [85] . Thus, limited studies on primate models
indicate that systemic administration of nontagged TRAIL
to cancer patients is unlikely to be toxic.
Temperature also changes the affinity of TRAIL to its
receptor as examined in in vitro studies [125] . Death
receptors (TRAIL-R1, TRAIL-R2, TRAIL-R3, and OPG)
have similar affinities for TRAIL at 48C, but their affinities
significantly differ at 378C, with TRAIL-R2 having the highest
and OPG having the weakest. Thus, the physiological
temperature could be an important determinant for TRAIL
signaling in pathophysiological situations. Further studies
are needed to evaluate the significance TRAIL binding to its
receptors in vivo.
Analysis of the DR-DISC components provides evidence
for the importance of caspase-8 in TRAIL- induced apopto-
sis. Such analysis failed to identify a similar function for
caspase-10, which was suggested by overexpression
studies [91,136] . The dendritic cells expressing a mutant
caspase-10 are resistant to TRAIL signaling [136] . Alter-
natively, a catalytically inactive caspase-10 mutant may act
as a nonreleasable substrate trap for caspase-8, thereby
inactivating the caspase, as has been proposed for FLIP
[49] . TRAIL signaling pathway may therefore, differ in cells
from different origins. However, identification of components
present in DISC provides a reliable method of identifying the
initial events of TRAIL- induced apoptosis.
Examination of TRAIL- induced apoptosis in vitro has
demonstrated that there are both TRAIL-sensitive and
TRAIL-resistant human melanoma and colon carcinoma
cell lines [6,38,63,122,133] . The reason for the differential
sensitivity remains unknown, but it is not regulated solely by
the differential expression of the known TRAIL receptors
[38] . Instead, it appears that intracellular inhibitor (s) acting
downstream of the TRAIL receptors renders some trans-
formed cells insensitive to TRAIL [38] . Addition of protein
synthesis inhibitors to TRAIL- resistant melanomas renders
them sensitive to TRAIL, indicating that the presence of
intracellular apoptosis inhibitors may mediate resistance to
TRAIL-mediated apoptosis [38] . Expression of FLIP is
highest in the TRAIL-resistant melanomas, being low or
undetectable in the TRAIL-sensitive melanomas [39] .
Furthermore, addition of actinomycin D to TRAIL-resistant
melanomas resulted in decreased intracellular concentra-
tions of FLIP, which correlated with their effectiveness of
TRAIL sensitivity [38] . In HeLa cells, apoptosis induction by
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TRAIL is dependent on the presence of cycloheximide
[130] . Interestingly, cycloheximide downregulates cFLIP,
and overexpression of cFLIP inhibited death receptor -
induced NFB activation [130] . This suggests a novel
functional role of cFLIP as a negative regulator of gene
induction and apoptosis. Furthermore, treatment of resistant
cells with some anticancer drugs renders cells sensitive to
TRAIL. For example, cisplatin and carboplatin enhance the
sensitivity of bladder cancer cells to TRAIL [82] .
Some prostate cancer cells express constitutively active
Akt /protein kinase B due to a complete loss of lipid
phosphatase PTEN gene [50,75,129,137] , a negative
regulator of PI-3 kinase pathway. Constitutively active Akt /
PKB promotes cellular survival and resistance to chemo-
therapy and radiation [22,105,116] . We and others have
shown that some human prostate cancer cells are resistant
to TRAIL [12,84] . Cell line expressing the highest level of
constitutively active Akt was most resistant to undergo
apoptosis by TRAIL than those expressing the lowest level
[12,84] . Downregulation of constitutively active Akt by PI-3
kinase inhibitors, wortmannin and LY294002, reverses
cellular resistance to TRAIL [12,84,123] . Treatment of
resistant cells with cycloheximide (a protein synthesis
inhibitor ) renders cells sensitive to TRAIL. Transfecting
dominant negative Akt decreased Akt activity and increased
TRAIL- induced apoptosis in cells with high Akt activity.
Conversely, transfecting constitutively active Akt into cells
with low Akt activity increased Akt activity and attenuated
TRAIL- induced apoptosis. Inhibition of TRAIL sensitivity
occurs at the level of BID cleavage, as caspase-8 activity
was not affected. Enforced expression of antiapoptotic
protein Bcl -2 or Bcl -XL inhibits TRAIL- induced mitochon-
drial dysfunction and apoptosis [12,84,123] . We therefore,
identify Akt as a constitutively active kinase that promotes
survival of prostate cancer cells and demonstrate that
modulation of Akt activity, by pharmacological or genetic
approaches, alters the cellular responsiveness to TRAIL.
Thus, TRAIL, in combination with agents that downregulate
Akt activity, can be used to treat prostate cancer.
TRAIL as a Potential Chemotherapeutic Agent
Solid tumors such as breast and prostate cancer are
currently controlled through surgery and/or radiotherapy
protocols and frequently supported by adjuvant chemo-
therapy. Unfortunately, there are limited treatment options
available for the disease because chemo- and radiothera-
pies are largely ineffective, and metastatic disease fre-
quently redevelops even after surgery. Therefore, there is an
urgent need for novel and effective therapies against cancer.
Ligation of death receptors to induce apoptosis in tumor cells
has been proposed as a viable method of treating epithelial
cell derived cancers; unfortunately, the administration of
FasL and TNF has toxic effects [31,135] . The discovery of
TRAIL may offer less toxic effects on noncancerous cells.
Ligation of Fas receptors with FasL can also play a role in
chemotherapeutic drug- induced apoptosis in epithelial cells,
because FAS and/or FasL are upregulated following
exposure of cells to anticancer drugs such as etoposide
[57] and microtubule-damaging drugs [114] . Interestingly,
CD40 (a member of the TNF receptor superfamily ) ligation
with its receptors can also induce functional FasL, TRAIL,
and TNF in apoptosis-susceptible carcinoma cells and
upregulate expression of Fas [28] . The expression of DR4
and/or DR5 is more highly regulated than Fas. In addition to
chemotherapeutic drugs, ionizing radiation can also induce
DR4 and/or DR5 [13,32,65,140] . Thus, upregulation of DR4
and DR5 by anticancer drugs or irradiation may further
enhance the efficacy of TRAIL.
Combination of TRAIL with chemotherapeutic drugs (e.g.,
etoposide, camptothecin, doxorubicin, and 5- fluorouracil ) or
irradiation results in a synergistic apoptotic response
[3,13,32,33,61] . In addition, TRAIL synergizes with a
synthetic retinoid (CD437) in inducing apoptosis of human
lung cancer cells by upregulating DR5 [118] . Recent studies
have demonstrated that systemic TRAIL inhibits the growth
of breast and colon cancer xenografts in mice [3,135] . In
some cell types, DR5 expression is regulated in a p53-
dependent manner, whereas in other cells increased DR5
expression seems p53 independent [106] . p53 acts as a
tumor suppressor by inducing cell cycle arrest and apopto-
sis. It is well known that p53-mediated cell cycle arrest
involves in the activation of p21 WAF1/CIP1, a cyclin -CDK
inhibitor, whereas the mechanism of p53-mediated apopto-
sis appears to involve multiple downstream effector target
genes. TRAIL synergizes with radiation in inducing apoptosis
in p53 wild- type breast carcinoma cells, but not in p53
negative cell lines [13] . This suggests that p53 may mediate
synergistic interaction between radiation and TRAIL. One of
the mechanisms of this synergy is that p53 upregulates
mRNA expression of the DR5 receptors [106] . Radiation
also upregulates expression of the DR5 protein, but not the
DR4 protein [13] . By expressing more of the death receptor,
cells may then become sensitive to TRAIL. TRAIL and
radiation may also activate distinct apoptotic pathways,
which may converge and further amplify treatment response.
TRAIL is expressed on IFN-–stimulated peripheral
blood T cells [58] and IFN-stimulated human monocytes
and dendritic cells [30,41] . Cytokines IL2, IFNs or IL-15 can
induce expression of TRAIL on CD3-NK1.1+ NK cells
[60,143] . TRAIL-expressing CD4+ T cells and mouse NK
cells can mediate apoptosis in a TRAIL-specific fashion
[59,60] . It has recently been shown that TRAIL contributes
to IFN-–dependent NK cell protection from tumor meta-
stasis. Thus, TRAIL may play a role in the cytolytic effector
function of monocytes, CD4+ T lymphocytes, dendritic cells,
and NK cells. This would be important in viral clearance and
suppression of autoimmunity, as well as tumor immunity.
The several strategies that have now been described for
treating cancer by targeting death receptor expression are
likely to provide useful insights into the role of TRAIL function
in apoptosis. TRAIL appears to be a cancer -specific
cytotoxic agent, and it offers several additional advantages
for the cancer therapy. Furthermore, it may enhance the
antitumor potential of traditional chemotherapeutic drugs or
irradiation. Recent studies suggest the potential use of
542 Intracellular Mechanisms of TRAIL - induced Apoptosis Srivastava
Neoplasia . Vol. 3, No. 6, 2001
TRAIL in gene therapy against cancer. Testing of the
therapeutic potential of these strategies in treating tumors
now awaits the translation of these approaches in relevant in
vivo systems where both antitumor effectiveness and
complicating side effects on normal cell function can be
evaluated.
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